Do Idebenone and Vitamin Therapy Shorten the Time to Achieve Visual Recovery in Leber Hereditary Optic Neuropathy?

  title={Do Idebenone and Vitamin Therapy Shorten the Time to Achieve Visual Recovery in Leber Hereditary Optic Neuropathy?},
  author={Yukihiko Mashima and Kazuteru Kigasawa and Masato Wakakura and Yoshihisa Oguchi},
  journal={Journal of Neuro-Ophthalmology},
Objectives: The authors investigated the effectiveness of idebenone combined with vitamin B2 and vitamin C in the treatment of patients with Leber hereditary optic neuropathy (LHON) in an early stage as compared with untreated patients with LHON. These agents may stimulate the formation of ATP. Materials and Methods: For this retrospective study, the authors selected 28 outpatients with LHON from the Keio University Hospital. These patients were followed for 2 to 19 years from disease onset… 
Effects of Idebenone on Color Vision in Patients With Leber Hereditary Optic Neuropathy
This study confirms that protan and tritan color confusion is an early symptom in LHON and that treatment with idebenone can protect from loss of color vision, particularly in patients who are at imminent risk of further vision loss.
Therapeutic Effects of Idebenone on Leber Hereditary Optic Neuropathy
Evidence is provided that idebenone treatment may be beneficial in cases of LHON and that the influential factors governing outcomes are the VA and amplitude of the VEP at baseline.
Idebenone treatment in Leber's hereditary optic neuropathy: rationale and efficacy
Despite some remaining questions regarding the optimal treatment regimen, idebenone is currently the only therapeutic option for LHON patients and, thus, will become the benchmark treatment for other therapies to follow.
Idebenone treatment in Leber's hereditary optic neuropathy.
To evaluate retrospectively the efficacy of idebenone therapy, the results presented by Klopstock et al. (2011) concerning the RHODOS study on a clinical trial with Idebenone in Leber's hereditary optic neuropathy (LHON) were reviewed.
Evaluation of Leber's hereditary optic neuropathy patients prior to a gene therapy clinical trial
The effects of Leber hereditary optical neuropathy (LHON) gene therapy should be evaluated primarily based on visual acuity, and visual field, neural fiber thickness, and electrophysiology should be considered in the evaluation.
Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy
In the first complete randomized, placebo-controlled, double-blind clinical trial in LHON, 85 unselected patients with LHON ≥14 years of age were randomized to receive 900 mg/day of idebenone or placebo in a 2:1 ratio for 24 weeks, showing a consistent trend in visual acuity end-points.
Idebenone: A Review in Leber’s Hereditary Optic Neuropathy
Significant evidence is provided that oral idebenone 900 mg/day for 24 weeks has persistent beneficial effects in preventing further vision impairment and promoting vision recovery in patients with LHON relative to the natural course of the disease.
Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy.
In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in all but 1 of the 5 consecutively treated patients with LHON, suggesting that the previously described irreversible priming to retinal ganglion cell loss may be reversed.
Leber Hereditary Optic Neuropathy: Review of Treatment and Management
The management strategies for patients with LHON before, during, and after the loss of vision are summarized, the rationale and effectiveness of previous and current treatments are explained, and findings about emerging treatments are reported.
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy
This first randomized controlled trial in the mitochondrial disorder, Leber’s hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.